Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that Sage will
participate in a fireside chat presentation at the BMO Prescriptions for
Success Healthcare Conference on Thursday, December 14, 2017 at 1:30
P.M. ET in New York.

A live webcast of the presentation can be accessed on the investor page
of Sage’s website at investor.sagerx.com. A replay of the webcast will
also be archived for up to 30 days on Sage’s website following the
conference.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders. Sage
has a portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage’s lead program, a proprietary IV
formulation of brexanolone (SAGE-547), has completed two Phase 3
clinical trials in postpartum depression. Sage is developing its next
generation modulators, including SAGE-217 and SAGE-718, in various CNS
disorders. For more information, please visit www.sagerx.com.

Contacts

Investor Contact:
Sage Therapeutics
Paul Cox,
617-299-8377
paul.cox@sagerx.com
or
Media
Contact:

Suda Communications LLC
Maureen L. Suda,
585-387-9248
maureen.suda@sagerx.com